| abstract |
Disclosed is the use of an isolated population of bone marrow-derived self-renewing colony-forming somatic cells (CF-SC) in the manufacture of a medicament to stimulate or enhance angiogenesis, wherein said CF-SC do not have multipotent differentiation capacity, wherein said CF-SC have a normal karyotype, wherein said CF-SC are non-immortalized, wherein said CF-SC express CD13, CD44, CD49c, CD90, HLA Class-1 and â (beta) 2-Microglobulin, and wherein said CF-SC do not express CD10, CD34, CD45, CD62L, or CD106. Further disclosed is a composition suitable for stimulating or enhancing angiogenesis comprising a pharmaceutically acceptable mixture of purified naturally occurring or isolated recombinant extracellular matrix or blood plasma proteins and bone marrow-derived self-renewing colony-forming somatic cells (CF-SC), wherein said CF-SC have a normal karyotype, wherein said CF-SC are non-immortalized, wherein said CF-SC express CD13, CD44, CD49c, CD90, HLA Class-1 and â (beta) 2-Microglobulin, and wherein said CF-SC do not express CD10, CD34, CD45, CD62L, or CD106. |